129 related articles for article (PubMed ID: 38508327)
21. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
[TBL] [Abstract][Full Text] [Related]
22. PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.
Chen L; Xiong Y; Li J; Zheng X; Zhou Q; Turner A; Wu C; Lu B; Jiang J
Cell Physiol Biochem; 2017; 42(6):2267-2280. PubMed ID: 28848143
[TBL] [Abstract][Full Text] [Related]
23. ZEB1-mediated vasculogenic mimicry formation associates with epithelial-mesenchymal transition and cancer stem cell phenotypes in prostate cancer.
Wang H; Huang B; Li BM; Cao KY; Mo CQ; Jiang SJ; Pan JC; Wang ZR; Lin HY; Wang DH; Qiu SP
J Cell Mol Med; 2018 Aug; 22(8):3768-3781. PubMed ID: 29754422
[TBL] [Abstract][Full Text] [Related]
24. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Hong W; Xue M; Jiang J; Zhang Y; Gao X
J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
[TBL] [Abstract][Full Text] [Related]
25. IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer.
Liao H; Chang X; Gao L; Ye C; Qiao Y; Xie L; Lin J; Cai S; Dong H
J Transl Med; 2023 Nov; 21(1):828. PubMed ID: 37978543
[TBL] [Abstract][Full Text] [Related]
26. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells.
Takeyama Y; Sato M; Horio M; Hase T; Yoshida K; Yokoyama T; Nakashima H; Hashimoto N; Sekido Y; Gazdar AF; Minna JD; Kondo M; Hasegawa Y
Cancer Lett; 2010 Oct; 296(2):216-24. PubMed ID: 20452118
[TBL] [Abstract][Full Text] [Related]
28. Programmed death-ligand 1 expression in non-small cell lung carcinoma - mechanism of regulation, association with other markers, and therapeutic implication.
Tancoš V; Blichárová A; Plank L
Klin Onkol; 2022; 35(5):372-376. PubMed ID: 36443097
[TBL] [Abstract][Full Text] [Related]
29. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of ZNF746 suppresses invasion and epithelial to mesenchymal transition in H460 non-small cell lung cancer cells.
Kim B; Sohn EJ; Jung JH; Shin EA; You OH; Im J; Kim SH
Oncol Rep; 2014 Jan; 31(1):73-8. PubMed ID: 24145959
[TBL] [Abstract][Full Text] [Related]
31. Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Mao R; Tan X; Xiao Y; Wang X; Wei Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Sci; 2020 Sep; 111(9):3174-3183. PubMed ID: 32539182
[TBL] [Abstract][Full Text] [Related]
32. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Chen L; Gibbons DL; Goswami S; Cortez MA; Ahn YH; Byers LA; Zhang X; Yi X; Dwyer D; Lin W; Diao L; Wang J; Roybal J; Patel M; Ungewiss C; Peng D; Antonia S; Mediavilla-Varela M; Robertson G; Suraokar M; Welsh JW; Erez B; Wistuba II; Chen L; Peng D; Wang S; Ullrich SE; Heymach JV; Kurie JM; Qin FX
Nat Commun; 2014 Oct; 5():5241. PubMed ID: 25348003
[TBL] [Abstract][Full Text] [Related]
33. Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer.
Bae GY; Choi SJ; Lee JS; Jo J; Lee J; Kim J; Cha HJ
Oncotarget; 2013 Dec; 4(12):2512-22. PubMed ID: 24318272
[TBL] [Abstract][Full Text] [Related]
34. PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
Kumar M; Jaiswal RK; Prasad R; Yadav SS; Kumar A; Yadava PK; Singh RP
Life Sci; 2021 Mar; 269():118994. PubMed ID: 33417952
[TBL] [Abstract][Full Text] [Related]
35. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
[TBL] [Abstract][Full Text] [Related]
36. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
37. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
[TBL] [Abstract][Full Text] [Related]
38. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
39. The α5-nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion.
Zhu P; Kang G; Jiao Y; Gui C; Fan H; Li X; Jia Y; Zhang L; Ma X
Hum Cell; 2022 Jul; 35(4):1207-1218. PubMed ID: 35593989
[TBL] [Abstract][Full Text] [Related]
40. Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
Koh YW; Han JH; Haam S
Pathology; 2021 Feb; 53(2):239-246. PubMed ID: 33036771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
